secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001104659-23-036263
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics appoints Matthew Klein as CEO; founder Stuart Peltz retires
----------------------------------------------------------------------------

- Stuart Peltz retires after 25 years as CEO; Matthew Klein appointed CEO and President, effective March 22, 2023.
- Peltz will serve as Senior Advisor & join Scientific Advisory Board; consulting fee of $600k for first 12 months, then $400k.
- Klein had been COO since Jan 2022; previously Global Head of Gene & Mitochondrial Therapies and Chief Development Officer.
- Peltz receives prorated 2023 annual bonus equal to 25% of his 2022 bonus; unvested equity continues vesting during consulting period.
- PTC's broad pipeline includes five registration-directed trials; Klein led EMA approval of Upstaza gene therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/0001104659-23-036263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465923036263/tm2310367d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-036263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer